Genmab A/S (NASDAQ:GMAB) Rating Increased to Hold at BNP Paribas

Genmab A/S (NASDAQ:GMAB) was upgraded by equities researchers at BNP Paribas from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Several other brokerages have also recently issued reports on GMAB. BMO Capital Markets restated an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Thursday, January 23rd. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a report on Thursday. Finally, Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Genmab A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.17.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $19.69 on Tuesday. The company has a market cap of $13.03 billion, a price-to-earnings ratio of 19.12, a PEG ratio of 0.54 and a beta of 0.96. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $31.88. The stock’s 50 day simple moving average is $20.68 and its two-hundred day simple moving average is $23.21.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. As a group, analysts anticipate that Genmab A/S will post 1.25 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently modified their holdings of the business. Brandywine Global Investment Management LLC purchased a new position in Genmab A/S during the 4th quarter valued at $33,804,000. Two Sigma Advisers LP lifted its position in shares of Genmab A/S by 84.1% during the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after purchasing an additional 280,900 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Genmab A/S by 18,959.1% during the fourth quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company’s stock valued at $10,660,000 after purchasing an additional 508,104 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Genmab A/S by 3,049.3% in the fourth quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company’s stock worth $8,507,000 after purchasing an additional 394,670 shares during the last quarter. Finally, Trexquant Investment LP increased its stake in Genmab A/S by 495.1% in the 4th quarter. Trexquant Investment LP now owns 379,936 shares of the company’s stock worth $7,929,000 after buying an additional 316,089 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.